 Michael Strong
Concepts (400)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium Infections, Nontuberculous | 27 | 2025 | 357 | 6.010 |
Why?
| | Genome, Bacterial | 15 | 2024 | 140 | 3.950 |
Why?
| | Mycobacterium | 11 | 2023 | 110 | 3.610 |
Why?
| | Nontuberculous Mycobacteria | 16 | 2024 | 201 | 3.250 |
Why?
| | Mycobacterium tuberculosis | 19 | 2023 | 315 | 2.760 |
Why?
| | Mycobacterium abscessus | 12 | 2025 | 115 | 2.430 |
Why?
| | Whole Genome Sequencing | 5 | 2025 | 157 | 1.710 |
Why?
| | Mycobacterium Infections | 6 | 2021 | 62 | 1.580 |
Why?
| | Neurodegenerative Diseases | 8 | 2025 | 138 | 1.510 |
Why?
| | Cystic Fibrosis | 13 | 2025 | 1102 | 1.370 |
Why?
| | Tuberculosis | 8 | 2023 | 280 | 1.300 |
Why?
| | Frontotemporal Dementia | 4 | 2023 | 57 | 1.160 |
Why?
| | Genomics | 7 | 2021 | 796 | 1.150 |
Why?
| | Phylogeny | 14 | 2021 | 998 | 1.040 |
Why?
| | Genotype | 6 | 2024 | 1842 | 0.980 |
Why?
| | Antitubercular Agents | 8 | 2023 | 203 | 0.960 |
Why?
| | Amyotrophic Lateral Sclerosis | 2 | 2017 | 96 | 0.920 |
Why?
| | Bacteriophages | 3 | 2022 | 98 | 0.890 |
Why?
| | Genome, Viral | 3 | 2021 | 222 | 0.870 |
Why?
| | Computational Biology | 9 | 2018 | 649 | 0.860 |
Why?
| | Lung Diseases | 3 | 2022 | 785 | 0.860 |
Why?
| | Methylobacterium | 1 | 2023 | 3 | 0.830 |
Why?
| | Sequence Analysis, DNA | 8 | 2022 | 819 | 0.800 |
Why?
| | High-Throughput Nucleotide Sequencing | 6 | 2022 | 540 | 0.790 |
Why?
| | Protein Domains | 1 | 2024 | 288 | 0.770 |
Why?
| | Herpesvirus 4, Human | 5 | 2016 | 165 | 0.770 |
Why?
| | Drug Resistance, Bacterial | 8 | 2024 | 184 | 0.750 |
Why?
| | Genetic Variation | 8 | 2021 | 986 | 0.740 |
Why?
| | Viral Nonstructural Proteins | 1 | 2021 | 65 | 0.700 |
Why?
| | Databases, Genetic | 3 | 2018 | 241 | 0.680 |
Why?
| | Lysogeny | 1 | 2020 | 5 | 0.680 |
Why?
| | Prophages | 1 | 2020 | 7 | 0.670 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 119 | 0.670 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2020 | 649 | 0.660 |
Why?
| | DNA-Binding Proteins | 5 | 2024 | 1471 | 0.640 |
Why?
| | Bacterial Proteins | 10 | 2016 | 892 | 0.640 |
Why?
| | Plasmids | 1 | 2020 | 358 | 0.630 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1941 | 0.620 |
Why?
| | Cross Infection | 4 | 2025 | 249 | 0.600 |
Why?
| | Viruses | 1 | 2021 | 161 | 0.600 |
Why?
| | Hawaii | 5 | 2023 | 36 | 0.590 |
Why?
| | Humans | 77 | 2025 | 138651 | 0.570 |
Why?
| | Mutation | 3 | 2021 | 3987 | 0.570 |
Why?
| | Soil Microbiology | 2 | 2020 | 209 | 0.570 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2021 | 2113 | 0.560 |
Why?
| | Equipment Contamination | 2 | 2016 | 71 | 0.560 |
Why?
| | Microbial Sensitivity Tests | 5 | 2024 | 351 | 0.550 |
Why?
| | DNA, Bacterial | 5 | 2021 | 335 | 0.550 |
Why?
| | Tissue Adhesives | 1 | 2017 | 23 | 0.520 |
Why?
| | Dura Mater | 1 | 2017 | 34 | 0.520 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2017 | 62 | 0.490 |
Why?
| | Respiratory System | 1 | 2017 | 157 | 0.490 |
Why?
| | Research Personnel | 1 | 2018 | 182 | 0.480 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2021 | 346 | 0.480 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2016 | 75 | 0.470 |
Why?
| | Cardiac Surgical Procedures | 2 | 2019 | 578 | 0.470 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 313 | 0.470 |
Why?
| | Viral Matrix Proteins | 1 | 2015 | 30 | 0.470 |
Why?
| | Frontotemporal Lobar Degeneration | 1 | 2015 | 18 | 0.470 |
Why?
| | Software | 5 | 2022 | 668 | 0.460 |
Why?
| | Databases, Nucleic Acid | 1 | 2014 | 38 | 0.440 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2015 | 120 | 0.440 |
Why?
| | Disease Outbreaks | 4 | 2025 | 416 | 0.440 |
Why?
| | Cerebrovascular Disorders | 2 | 2025 | 96 | 0.430 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2015 | 98 | 0.420 |
Why?
| | Stomach Neoplasms | 1 | 2015 | 117 | 0.420 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2015 | 205 | 0.420 |
Why?
| | Skin Diseases, Bacterial | 1 | 2013 | 21 | 0.410 |
Why?
| | Genetic Predisposition to Disease | 3 | 2019 | 2339 | 0.410 |
Why?
| | Systems Biology | 1 | 2014 | 70 | 0.400 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 496 | 0.400 |
Why?
| | Microbiota | 1 | 2021 | 758 | 0.400 |
Why?
| | Tuberculosis, Pulmonary | 4 | 2016 | 141 | 0.390 |
Why?
| | tau Proteins | 5 | 2025 | 92 | 0.380 |
Why?
| | Respiratory Tract Diseases | 1 | 2014 | 181 | 0.370 |
Why?
| | Ontario | 6 | 2025 | 94 | 0.350 |
Why?
| | Cognition Disorders | 1 | 2015 | 511 | 0.350 |
Why?
| | Cognitive Dysfunction | 4 | 2025 | 392 | 0.350 |
Why?
| | Molybdenum | 2 | 2021 | 9 | 0.350 |
Why?
| | Sputum | 6 | 2021 | 305 | 0.330 |
Why?
| | Metagenomics | 2 | 2021 | 177 | 0.320 |
Why?
| | Hydrogels | 1 | 2017 | 680 | 0.320 |
Why?
| | Alzheimer Disease | 3 | 2023 | 564 | 0.310 |
Why?
| | Protein Binding | 4 | 2024 | 2225 | 0.310 |
Why?
| | Physicians | 1 | 2018 | 932 | 0.300 |
Why?
| | Proteins | 3 | 2014 | 1006 | 0.300 |
Why?
| | Lung | 6 | 2023 | 4106 | 0.290 |
Why?
| | RNA, Viral | 2 | 2024 | 684 | 0.290 |
Why?
| | RNA | 2 | 2014 | 925 | 0.280 |
Why?
| | United States | 10 | 2022 | 14938 | 0.280 |
Why?
| | Proteomics | 4 | 2010 | 1110 | 0.270 |
Why?
| | Genes, Bacterial | 4 | 2017 | 166 | 0.260 |
Why?
| | Gene Expression Profiling | 9 | 2023 | 1746 | 0.260 |
Why?
| | Canada | 2 | 2018 | 407 | 0.240 |
Why?
| | Chromosome Mapping | 2 | 2023 | 502 | 0.240 |
Why?
| | Treatment Outcome | 3 | 2017 | 10923 | 0.240 |
Why?
| | Bacterial Typing Techniques | 2 | 2017 | 43 | 0.240 |
Why?
| | Cluster Analysis | 4 | 2014 | 517 | 0.230 |
Why?
| | Tuberculosis, Multidrug-Resistant | 3 | 2016 | 58 | 0.220 |
Why?
| | DNA Mutational Analysis | 2 | 2016 | 398 | 0.220 |
Why?
| | Evolution, Molecular | 2 | 2021 | 506 | 0.220 |
Why?
| | Virulence | 3 | 2020 | 262 | 0.220 |
Why?
| | Soil | 3 | 2022 | 204 | 0.220 |
Why?
| | Microvessels | 1 | 2025 | 86 | 0.210 |
Why?
| | DNA Repeat Expansion | 2 | 2014 | 12 | 0.210 |
Why?
| | Reference Standards | 1 | 2024 | 184 | 0.210 |
Why?
| | Immunity, Innate | 3 | 2021 | 824 | 0.210 |
Why?
| | Gene Expression | 2 | 2021 | 1488 | 0.210 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2024 | 102 | 0.210 |
Why?
| | Brain | 3 | 2025 | 2792 | 0.210 |
Why?
| | Neuropsychological Tests | 3 | 2017 | 1058 | 0.200 |
Why?
| | White Matter | 1 | 2025 | 144 | 0.200 |
Why?
| | Multigene Family | 1 | 2003 | 201 | 0.200 |
Why?
| | Data Accuracy | 1 | 2023 | 65 | 0.200 |
Why?
| | Transcriptome | 4 | 2023 | 967 | 0.200 |
Why?
| | Gene Expression Regulation, Bacterial | 5 | 2023 | 318 | 0.190 |
Why?
| | Virus Replication | 2 | 2016 | 527 | 0.190 |
Why?
| | Phosphoproteins | 1 | 2024 | 338 | 0.180 |
Why?
| | Protein Conformation, beta-Strand | 1 | 2021 | 18 | 0.180 |
Why?
| | Protein Conformation, alpha-Helical | 1 | 2021 | 19 | 0.180 |
Why?
| | Furin | 1 | 2021 | 14 | 0.180 |
Why?
| | Asia | 1 | 2021 | 70 | 0.180 |
Why?
| | Africa | 1 | 2021 | 118 | 0.180 |
Why?
| | Biomedical Research | 2 | 2018 | 694 | 0.180 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 110 | 0.180 |
Why?
| | Epidemiological Monitoring | 1 | 2021 | 64 | 0.180 |
Why?
| | Adenosine Monophosphate | 1 | 2021 | 67 | 0.180 |
Why?
| | Genome Size | 1 | 2020 | 11 | 0.170 |
Why?
| | Transcription, Genetic | 6 | 2023 | 1470 | 0.170 |
Why?
| | Alanine | 1 | 2021 | 152 | 0.170 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 150 | 0.170 |
Why?
| | Models, Molecular | 3 | 2016 | 1587 | 0.170 |
Why?
| | Europe | 1 | 2021 | 407 | 0.170 |
Why?
| | Amino Acid Substitution | 1 | 2021 | 309 | 0.170 |
Why?
| | Structure-Activity Relationship | 2 | 2016 | 575 | 0.170 |
Why?
| | Water Pollution | 1 | 2020 | 9 | 0.170 |
Why?
| | Bacteriological Techniques | 1 | 2021 | 67 | 0.170 |
Why?
| | Metagenome | 1 | 2021 | 149 | 0.160 |
Why?
| | Water Quality | 1 | 2020 | 33 | 0.160 |
Why?
| | Killer Cells, Natural | 2 | 2014 | 461 | 0.160 |
Why?
| | Middle Aged | 13 | 2025 | 33604 | 0.160 |
Why?
| | Antigens, Bacterial | 2 | 2014 | 125 | 0.160 |
Why?
| | Immune Evasion | 1 | 2020 | 58 | 0.160 |
Why?
| | Bone Neoplasms | 1 | 2022 | 246 | 0.160 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2020 | 81 | 0.150 |
Why?
| | Adaptation, Physiological | 3 | 2023 | 548 | 0.150 |
Why?
| | Membrane Lipids | 1 | 2020 | 91 | 0.150 |
Why?
| | Aged | 11 | 2025 | 24024 | 0.150 |
Why?
| | Bone and Bones | 1 | 2022 | 317 | 0.150 |
Why?
| | Apolipoproteins E | 1 | 2019 | 91 | 0.150 |
Why?
| | Pneumonia | 2 | 2023 | 644 | 0.150 |
Why?
| | Male | 19 | 2025 | 68260 | 0.150 |
Why?
| | Protein Conformation | 2 | 2016 | 936 | 0.150 |
Why?
| | Phospholipids | 1 | 2020 | 219 | 0.140 |
Why?
| | Binding Sites | 1 | 2021 | 1313 | 0.140 |
Why?
| | Databases, Factual | 2 | 2021 | 1415 | 0.140 |
Why?
| | Host-Pathogen Interactions | 3 | 2016 | 368 | 0.140 |
Why?
| | Training Support | 1 | 2018 | 37 | 0.140 |
Why?
| | Mycolic Acids | 1 | 2017 | 7 | 0.140 |
Why?
| | Longitudinal Studies | 3 | 2025 | 2844 | 0.140 |
Why?
| | Fomites | 1 | 2017 | 7 | 0.140 |
Why?
| | Neurofilament Proteins | 2 | 2025 | 51 | 0.140 |
Why?
| | Base Composition | 1 | 2017 | 78 | 0.140 |
Why?
| | Virus Diseases | 1 | 2020 | 214 | 0.140 |
Why?
| | Oregon | 1 | 2017 | 73 | 0.140 |
Why?
| | Adult | 13 | 2025 | 38201 | 0.130 |
Why?
| | Biological Specimen Banks | 1 | 2018 | 98 | 0.130 |
Why?
| | Valsalva Maneuver | 1 | 2017 | 9 | 0.130 |
Why?
| | Disease | 1 | 2018 | 102 | 0.130 |
Why?
| | Anti-Bacterial Agents | 3 | 2022 | 1818 | 0.130 |
Why?
| | Water Supply | 1 | 2017 | 78 | 0.130 |
Why?
| | Surgical Equipment | 1 | 2016 | 10 | 0.130 |
Why?
| | Sensation Disorders | 1 | 2017 | 37 | 0.130 |
Why?
| | Brazil | 2 | 2014 | 166 | 0.130 |
Why?
| | DNA Gyrase | 1 | 2016 | 12 | 0.130 |
Why?
| | Gait Disorders, Neurologic | 1 | 2017 | 47 | 0.120 |
Why?
| | Fluoroquinolones | 1 | 2016 | 42 | 0.120 |
Why?
| | Web Browser | 1 | 2015 | 13 | 0.120 |
Why?
| | DNA Barcoding, Taxonomic | 1 | 2015 | 22 | 0.120 |
Why?
| | Gene Ontology | 1 | 2015 | 53 | 0.120 |
Why?
| | Catalase | 1 | 2016 | 134 | 0.120 |
Why?
| | Guidelines as Topic | 1 | 2018 | 272 | 0.120 |
Why?
| | Antiviral Agents | 1 | 2021 | 735 | 0.120 |
Why?
| | Isoniazid | 1 | 2016 | 61 | 0.120 |
Why?
| | Language Disorders | 1 | 2015 | 30 | 0.120 |
Why?
| | Molecular Sequence Annotation | 1 | 2015 | 95 | 0.120 |
Why?
| | Career Choice | 1 | 2018 | 229 | 0.120 |
Why?
| | Mentors | 1 | 2018 | 209 | 0.120 |
Why?
| | Social Perception | 1 | 2017 | 106 | 0.120 |
Why?
| | Rifampin | 1 | 2016 | 84 | 0.120 |
Why?
| | Mouth Mucosa | 1 | 2016 | 90 | 0.120 |
Why?
| | Bacterial Toxins | 1 | 2016 | 104 | 0.120 |
Why?
| | Cohort Studies | 6 | 2025 | 5697 | 0.120 |
Why?
| | Octamer Transcription Factors | 1 | 2015 | 3 | 0.120 |
Why?
| | Housing | 1 | 2016 | 142 | 0.120 |
Why?
| | Nuclear Matrix-Associated Proteins | 1 | 2015 | 6 | 0.120 |
Why?
| | Genes, Viral | 1 | 2015 | 92 | 0.120 |
Why?
| | Virus Activation | 1 | 2016 | 86 | 0.120 |
Why?
| | Tumor Escape | 1 | 2015 | 43 | 0.110 |
Why?
| | Neurosurgical Procedures | 1 | 2017 | 204 | 0.110 |
Why?
| | Female | 15 | 2025 | 73763 | 0.110 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 553 | 0.110 |
Why?
| | Data Mining | 1 | 2016 | 115 | 0.110 |
Why?
| | Herpesviridae | 1 | 2014 | 22 | 0.110 |
Why?
| | Neuroimaging | 1 | 2017 | 263 | 0.110 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2015 | 99 | 0.110 |
Why?
| | Adaptive Immunity | 1 | 2016 | 171 | 0.110 |
Why?
| | Viral Core Proteins | 1 | 2014 | 21 | 0.110 |
Why?
| | Education, Medical | 1 | 2018 | 268 | 0.110 |
Why?
| | Retroviridae | 1 | 2014 | 103 | 0.110 |
Why?
| | Tuberculosis Vaccines | 1 | 2014 | 5 | 0.110 |
Why?
| | Genetic Linkage | 2 | 2006 | 288 | 0.110 |
Why?
| | Colorado | 5 | 2024 | 4555 | 0.110 |
Why?
| | Postural Balance | 1 | 2017 | 217 | 0.110 |
Why?
| | Aged, 80 and over | 6 | 2025 | 7677 | 0.110 |
Why?
| | Biofilms | 1 | 2016 | 265 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 3 | 2025 | 3637 | 0.100 |
Why?
| | Language | 1 | 2017 | 305 | 0.100 |
Why?
| | Biomarkers | 3 | 2025 | 4092 | 0.100 |
Why?
| | RNA, Untranslated | 1 | 2015 | 124 | 0.100 |
Why?
| | Operon | 2 | 2003 | 65 | 0.100 |
Why?
| | Extracellular Vesicles | 1 | 2016 | 148 | 0.100 |
Why?
| | Survival Analysis | 1 | 2017 | 1309 | 0.100 |
Why?
| | Brain Concussion | 1 | 2021 | 579 | 0.100 |
Why?
| | B-Lymphocytes | 2 | 2016 | 855 | 0.100 |
Why?
| | Heterozygote | 1 | 2014 | 305 | 0.100 |
Why?
| | Conserved Sequence | 2 | 2003 | 238 | 0.100 |
Why?
| | Lymphoma | 1 | 2014 | 227 | 0.100 |
Why?
| | Galectins | 1 | 2013 | 24 | 0.100 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5520 | 0.100 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2020 | 657 | 0.100 |
Why?
| | Hepacivirus | 1 | 2014 | 238 | 0.100 |
Why?
| | Phenotype | 3 | 2016 | 3139 | 0.100 |
Why?
| | Virulence Factors | 1 | 2014 | 157 | 0.100 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1482 | 0.090 |
Why?
| | Epidemics | 1 | 2013 | 91 | 0.090 |
Why?
| | Genetic Association Studies | 1 | 2014 | 370 | 0.090 |
Why?
| | Motor Activity | 1 | 2017 | 710 | 0.090 |
Why?
| | Amyloid beta-Peptides | 2 | 2025 | 229 | 0.090 |
Why?
| | Herpesviridae Infections | 1 | 2013 | 148 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2023 | 2053 | 0.090 |
Why?
| | Sequence Analysis, RNA | 1 | 2014 | 448 | 0.090 |
Why?
| | RNA-Binding Proteins | 1 | 2015 | 431 | 0.090 |
Why?
| | DNA, Viral | 1 | 2012 | 365 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5112 | 0.080 |
Why?
| | Nerve Tissue Proteins | 1 | 2014 | 600 | 0.080 |
Why?
| | Base Sequence | 1 | 2013 | 2174 | 0.080 |
Why?
| | Case-Control Studies | 4 | 2021 | 3523 | 0.080 |
Why?
| | Mice, Inbred C57BL | 4 | 2023 | 5798 | 0.080 |
Why?
| | Epithelial Cells | 1 | 2016 | 1102 | 0.080 |
Why?
| | Time Factors | 2 | 2021 | 6851 | 0.080 |
Why?
| | Activities of Daily Living | 2 | 2023 | 421 | 0.080 |
Why?
| | MicroRNAs | 1 | 2016 | 675 | 0.080 |
Why?
| | Species Specificity | 2 | 2020 | 581 | 0.070 |
Why?
| | Young Adult | 4 | 2017 | 13305 | 0.070 |
Why?
| | Bayes Theorem | 2 | 2021 | 412 | 0.070 |
Why?
| | Signal Transduction | 2 | 2016 | 5086 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2015 | 2851 | 0.070 |
Why?
| | Cell Wall | 2 | 2006 | 57 | 0.070 |
Why?
| | Public Health | 1 | 2012 | 580 | 0.070 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2590 | 0.060 |
Why?
| | Mice | 5 | 2023 | 17814 | 0.060 |
Why?
| | Treatment Failure | 2 | 2021 | 351 | 0.060 |
Why?
| | Uganda | 2 | 2016 | 85 | 0.060 |
Why?
| | Solubility | 1 | 2006 | 242 | 0.060 |
Why?
| | Disease Models, Animal | 3 | 2023 | 4315 | 0.060 |
Why?
| | Cloning, Molecular | 1 | 2006 | 533 | 0.060 |
Why?
| | Diffusion Tensor Imaging | 1 | 2025 | 76 | 0.060 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2025 | 102 | 0.060 |
Why?
| | Crystallography, X-Ray | 1 | 2006 | 477 | 0.060 |
Why?
| | Atrophy | 1 | 2025 | 189 | 0.050 |
Why?
| | Protein Kinases | 2 | 2016 | 308 | 0.050 |
Why?
| | Arizona | 1 | 2024 | 81 | 0.050 |
Why?
| | C9orf72 Protein | 2 | 2014 | 12 | 0.050 |
Why?
| | Glutamate-Ammonia Ligase | 1 | 2003 | 7 | 0.050 |
Why?
| | Galactans | 1 | 2003 | 4 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 761 | 0.050 |
Why?
| | Iron | 2 | 2022 | 323 | 0.050 |
Why?
| | Mexico | 1 | 2024 | 232 | 0.050 |
Why?
| | Risk Factors | 3 | 2025 | 10252 | 0.050 |
Why?
| | Genome | 1 | 2006 | 299 | 0.050 |
Why?
| | Dust | 1 | 2023 | 98 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2018 | 3307 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2014 | 224 | 0.050 |
Why?
| | Animals | 6 | 2023 | 37217 | 0.050 |
Why?
| | Stem Cell Transplantation | 1 | 2024 | 184 | 0.050 |
Why?
| | Proteome | 2 | 2006 | 469 | 0.050 |
Why?
| | Mycobacterium avium Complex | 1 | 2023 | 87 | 0.050 |
Why?
| | Oxides | 1 | 2022 | 47 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2006 | 737 | 0.050 |
Why?
| | Clarithromycin | 1 | 2021 | 23 | 0.040 |
Why?
| | HIV Infections | 1 | 2016 | 2941 | 0.040 |
Why?
| | Armadillos | 1 | 2021 | 2 | 0.040 |
Why?
| | Mycobacterium leprae | 1 | 2021 | 9 | 0.040 |
Why?
| | Macrolides | 1 | 2021 | 67 | 0.040 |
Why?
| | Clone Cells | 1 | 2021 | 265 | 0.040 |
Why?
| | Cell Membrane | 2 | 2020 | 716 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2023 | 1032 | 0.040 |
Why?
| | Benchmarking | 1 | 2022 | 187 | 0.040 |
Why?
| | Smokers | 1 | 2021 | 144 | 0.040 |
Why?
| | Bone Marrow | 1 | 2022 | 299 | 0.040 |
Why?
| | Bioreactors | 1 | 2021 | 48 | 0.040 |
Why?
| | Macrophages | 2 | 2020 | 1543 | 0.040 |
Why?
| | Water | 1 | 2023 | 462 | 0.040 |
Why?
| | Microbial Viability | 1 | 2021 | 91 | 0.040 |
Why?
| | Spine | 1 | 2022 | 179 | 0.040 |
Why?
| | Chromatography, Thin Layer | 1 | 2020 | 27 | 0.040 |
Why?
| | THP-1 Cells | 1 | 2020 | 19 | 0.040 |
Why?
| | Cathelicidins | 1 | 2020 | 41 | 0.040 |
Why?
| | Glycolipids | 1 | 2020 | 42 | 0.040 |
Why?
| | Genetics, Population | 1 | 2021 | 206 | 0.040 |
Why?
| | Apolipoprotein E4 | 1 | 2019 | 37 | 0.040 |
Why?
| | Mice, Nude | 1 | 2021 | 688 | 0.040 |
Why?
| | Cell Line | 2 | 2015 | 2876 | 0.040 |
Why?
| | Global Health | 1 | 2021 | 383 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 669 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2016 | 2815 | 0.030 |
Why?
| | Behavior, Animal | 1 | 2021 | 512 | 0.030 |
Why?
| | Child | 3 | 2025 | 21921 | 0.030 |
Why?
| | Disease Progression | 1 | 2025 | 2749 | 0.030 |
Why?
| | Membrane Proteins | 2 | 2014 | 1145 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2012 | 2923 | 0.030 |
Why?
| | Gambia | 1 | 2016 | 8 | 0.030 |
Why?
| | Macrophages, Alveolar | 1 | 2020 | 396 | 0.030 |
Why?
| | Hospitals | 1 | 2021 | 695 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2014 | 3392 | 0.030 |
Why?
| | Regulon | 1 | 2016 | 36 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2023 | 958 | 0.030 |
Why?
| | Nitrogen Oxides | 1 | 2016 | 54 | 0.030 |
Why?
| | Granuloma | 1 | 2016 | 97 | 0.030 |
Why?
| | India | 1 | 2016 | 203 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 433 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1179 | 0.030 |
Why?
| | Palatine Tonsil | 1 | 2016 | 53 | 0.030 |
Why?
| | Body Temperature Regulation | 1 | 2016 | 100 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2025 | 15909 | 0.030 |
Why?
| | Escherichia coli | 1 | 2020 | 827 | 0.030 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2016 | 157 | 0.030 |
Why?
| | Replication Origin | 1 | 2015 | 21 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2016 | 188 | 0.030 |
Why?
| | Prevalence | 1 | 2022 | 2727 | 0.030 |
Why?
| | Latent Tuberculosis | 1 | 2015 | 68 | 0.030 |
Why?
| | Specimen Handling | 1 | 2016 | 180 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2016 | 215 | 0.030 |
Why?
| | CD56 Antigen | 1 | 2014 | 34 | 0.030 |
Why?
| | Ataxins | 1 | 2014 | 4 | 0.030 |
Why?
| | Survival of Motor Neuron 2 Protein | 1 | 2014 | 5 | 0.030 |
Why?
| | Adolescent | 3 | 2021 | 21564 | 0.030 |
Why?
| | Virus Integration | 1 | 2014 | 69 | 0.030 |
Why?
| | Survival of Motor Neuron 1 Protein | 1 | 2014 | 13 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2016 | 334 | 0.030 |
Why?
| | Accidental Falls | 1 | 2017 | 192 | 0.030 |
Why?
| | Multilocus Sequence Typing | 1 | 2014 | 16 | 0.030 |
Why?
| | Motor Neuron Disease | 1 | 2014 | 20 | 0.030 |
Why?
| | Lymphocyte Subsets | 1 | 2014 | 88 | 0.030 |
Why?
| | Saliva | 1 | 2016 | 238 | 0.030 |
Why?
| | Extracellular Space | 1 | 2014 | 129 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 562 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1482 | 0.030 |
Why?
| | Guinea Pigs | 1 | 2014 | 170 | 0.030 |
Why?
| | Cell Count | 1 | 2014 | 325 | 0.030 |
Why?
| | Burkitt Lymphoma | 1 | 2014 | 63 | 0.030 |
Why?
| | Autopsy | 1 | 2013 | 97 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 131 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2016 | 728 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1047 | 0.020 |
Why?
| | Muromegalovirus | 1 | 2013 | 23 | 0.020 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2013 | 30 | 0.020 |
Why?
| | Immunophenotyping | 1 | 2014 | 327 | 0.020 |
Why?
| | United Kingdom | 1 | 2014 | 319 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1296 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2017 | 565 | 0.020 |
Why?
| | Receptors, Virus | 1 | 2013 | 94 | 0.020 |
Why?
| | Interferons | 1 | 2014 | 195 | 0.020 |
Why?
| | Interleukin-15 | 1 | 2013 | 101 | 0.020 |
Why?
| | Interleukin-12 | 1 | 2013 | 123 | 0.020 |
Why?
| | Gene Deletion | 1 | 2014 | 388 | 0.020 |
Why?
| | Microtubule-Associated Proteins | 1 | 2013 | 195 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2014 | 309 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2013 | 385 | 0.020 |
Why?
| | Hepatitis C | 1 | 2014 | 246 | 0.020 |
Why?
| | Prospective Studies | 1 | 2023 | 7554 | 0.020 |
Why?
| | Drug Discovery | 1 | 2012 | 144 | 0.020 |
Why?
| | Genetic Testing | 1 | 2013 | 451 | 0.020 |
Why?
| | NF-kappa B | 1 | 2014 | 678 | 0.020 |
Why?
| | Viral Proteins | 1 | 2012 | 362 | 0.020 |
Why?
| | Hypoxia | 1 | 2016 | 1149 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1230 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2010 | 2155 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2010 | 1731 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2013 | 3028 | 0.010 |
Why?
| | Phosphorylation | 1 | 2010 | 1760 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2013 | 4181 | 0.010 |
Why?
| | Vaccination | 1 | 2014 | 1437 | 0.010 |
Why?
| | Biological Transport | 1 | 2006 | 403 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 5803 | 0.010 |
Why?
| | DNA Repair | 1 | 2006 | 229 | 0.010 |
Why?
| | Up-Regulation | 1 | 2006 | 851 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 2006 | 522 | 0.010 |
Why?
| | Amino Acids | 1 | 2006 | 496 | 0.010 |
Why?
|
|
Strong's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|